Endo withdraws abuse-deterrent labelling for Opana ER
Dublin, Ireland-based speciality pharma Endo International is withdrawing its US application to add abuse deterrent labelling to its long-acting opioid Opana ER.
Read More
Tag: Opana
- KOALA trial opens to enrol patients for first‑in‑human KMCAR T‑cell therapy
- Pepaxti study supports use in wider myeloma population
- UCB reports positive outcomes for bimekizumab in psoriatic arthritis
- AstraZeneca wins US approval for first‑in‑class Baxfendy in hypertension
- Cellbxhealth partners with AdventHealth on CTC‑based monitoring in two major cancer studies
